The publication of phase III data on cabazitaxel in the management of metastatic castrate-resistant prostate cancer in men previously treated with docetaxel demonstrated, for the first time, that a survival benefit can be achieved in this patient group. Optimal use of cabazitaxel will depend on appropriate patient selection and on effective management of the side effects, which have been shown to be predictable and preventable/treatable using interventions that are already familiar to chemotherapy clinics.
Get full access to this article
View all access options for this article.
References
1.
TannockIF, de WitR, BerryWR, HortiJ, PluzanskaA, ChiKNDocetaxel plus prednisolone or mitoxantrone plus prednisolone for advanced prostate cancer. N Engl J Med2004; 351: 1502–12.
2.
PetrylakDP, TangenCM, HussainMHA, LaraPN, JonesJA, TaplinMEDocetaxel and estramustine compared with mitoxantrone and prednisolone for advanced refractory prostate cancer. N Engl J Med2004; 351: 1513–20.
3.
National Institute for Health and Clinical Excellence. Docetaxel for the treatment of hormone-refractory metastatic prostate cancer. [Technology Appraisal 101). http://www.nice.org.uk/nicemedia/pdf/TA101guidance.pdf accessed April 2011].
de BonoJS, OudardS, OzgurogluM, HansenS, MachielsJ-P, KocakIPrednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet2010; 376: 1147–54.
6.
MitaAC, DenisLJ, RowinskyEK, de BonoJS, GoetzAD, OchoaLPhase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-h infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res2009; 15: 723–30.
SartorAO, OudardS, OzgurogluM, HansenS, MachielsJH, ShenLCabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final resultsof a multinational phase III trial (TROPIC). Presented at ASCO GU, San Francisco, March 2010; Abstract 9 (presentation).
RoachM, HanksG, ThamesH, SchellhammerP, ShipleyWU, SokolGHDefining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOGASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys2006; 65: 965–74.
12.
BeuzebocP.Re: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Eur Urol2011; 59: 658.
13.
AaproMS, CameronDA, PettengellR, BohliusJ, CrawfordJ, EllisMEORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer2006; 42: 2433–53.
14.
SmithTJ, KhatcheressianJ, LymanGH, OzerH, ArmitageJO, BalducciL2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol2006; 24: 3187–205.
AksoyDY, TanrioverMD, UzunO, ZarakoluP, ErcisS, ErguvenSDiarrhea in neutropenic patients: a prospective cohort study with emphasis on neutropenic enterocolitis. Ann Oncol2007; 18: 183–9.
19.
MinisiniAM, TostiA, SobreroAF, MansuttiM, PiracciniBM, SaccoCTaxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol2003; 14: 333–7.
20.
ScotteF, TouraniJM, BanuE, PeyromaureM, LevyE, MarsanSMulti-centre study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol2005; 23: 4424–9.
